Table 1.
Demographic, clinical characteristics, eradication rates per intention-to-treat, compliance and adverse events of patients in each therapeutics group
|
Dual H. pylori - resistance |
Triple H. pylori- resistance | |||
| C + M | C + L | M + L | C + M + L | |
| OAL-10 | OAM-10 | OAC-10 | OAR-10 | |
| (43) | (12) | (13) | (12) | |
| Gender (females) | 70% | 67% | 69% | 67% |
| Age (yr) | ||||
| Mean | 51.6 | 52.8 | 50 | 53.3 |
| Median (range) | 51 (18-76) | 52 (24-76) | 50 (31-75) | 53 (42-77) |
| Indication | ||||
| Dyspepsia | 95% | 83% | 84% | 75% |
| Ulcer | 5% | 17% | 16% | 25% |
| ITT eradication | 42/43 (97.6%) | 11/12 (91.6%) | 12/13 (92.3%) | 7/12 (58.3%) |
| Compliance | 93% | 93% | 93% | 94% |
| Adverse events | 22% | 25% | 23% | 17% |
O: Omeprazole; A: Amoxicillin; L: Levofloxacin; M: Metronidazole; C: Clarithromycin; R: Rifabutin; H. pylori: Helicobacter pylori; ITT: Intention-to-treat.